hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06277323, orgStudyIdInfo id: Cardio, briefTitle: UCLA Health Patient Cardiology Care Gaps, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-30, primaryCompletionDateStruct date: 2025-07-30, completionDateStruct date: 2025-07-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: University of California, Los Angeles, class: OTHER, collaborators name: UCLA Health Department of Medicine, descriptionModule briefSummary: This is a prospective randomized clinical trial evaluating how two behaviorally-informed interventions (i.e., monthly report card and storyboard interventions) impact physician behavior, with the goal of closing care gaps in preventive care and disease management.In particular, the monthly report card intervention seeks to elevate physicians' intentions to close their patients' care gaps, while the storyboard intervention seeks to prompt action by making patients' care gaps salient. The trial investigates the separate and joint impacts of the proposed behaviorally-informed interventions on encouraging physicians to close their patients' care gaps., conditionsModule conditions: Health Maintenance, conditions: Cardiology, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel randomized trial at the physician level., primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 46, type: ACTUAL, armsInterventionsModule interventions name: Monthly report card intervention, interventions name: Storyboard intervention, outcomesModule primaryOutcomes measure: Care gap closure (patients seen), secondaryOutcomes measure: Care gap closure (all patients in panel), secondaryOutcomes measure: Number of care gaps closed (patients seen), secondaryOutcomes measure: Number of care gaps closed (all patients in panel), secondaryOutcomes measure: HCC/RAF care gap closure (all patients in panel), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UCLA Health Department of Medicine, Quality Office, city: Los Angeles, state: California, zip: 90095, country: United States, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06277310, orgStudyIdInfo id: 3WP in SNH, briefTitle: Implementation of the 3 Wishes Project in Safety-Net Hospitals, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2028-04, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: University of California, Los Angeles, class: OTHER, collaborators name: Olive View-UCLA Education & Research Institute, collaborators name: LAC+USC Medical Center, descriptionModule briefSummary: Dignified and compassionate end-of-life (EOL) care is a cornerstone of high-quality, patient-centered care, but in safety-net hospitals EOL care is often overlooked, considered too late, or not at all. By eliciting and implementing final wishes for dying patients, the 3 Wishes Project (3WP) has demonstrated, in tertiary academic centers, that acts of compassion can improve the EOL experience and help families cope with loss. The investigators propose to implement the 3WP in safety-net hospitals where there are less resources and more diverse, disadvantaged patient populations, and hypothesize that there will be similar positive effects on the EOL experience for patients, families, and clinicians., conditionsModule conditions: End of Life, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This is a before and after stepped wedge study design, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 900, type: ESTIMATED, armsInterventionsModule interventions name: 3 Wishes Project, outcomesModule primaryOutcomes measure: Families' assessment of the quality of end-of-life, particularly in emotional and spiritual support., secondaryOutcomes measure: Family anxiety and depression, secondaryOutcomes measure: Nurse Burnout, secondaryOutcomes measure: Family PTSD, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: LA General Hospital, city: Los Angeles, state: California, zip: 90033, country: United States, geoPoint lat: 34.05223, lon: -118.24368, locations facility: Ronald Reagan UCLA Medical Center, city: Los Angeles, state: California, zip: 90095, country: United States, geoPoint lat: 34.05223, lon: -118.24368, locations facility: Olive View Medical Center, city: Sylmar, state: California, zip: 91342, country: United States, geoPoint lat: 34.30778, lon: -118.44925, locations facility: Harbor-UCLA, city: Torrance, state: California, zip: 90502, country: United States, geoPoint lat: 33.83585, lon: -118.34063, hasResults: False
protocolSection identificationModule nctId: NCT06277297, orgStudyIdInfo id: NP/2022/4583, briefTitle: Prognotic Role of CMR in Takotsubo Syndrome, acronym: EVOLUTION, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-09, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2032-11, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: University of Cagliari, class: OTHER, descriptionModule briefSummary: The primary objective of this observational registry is to develop a comprehensive clinical and imaging score (incorporating echocardiography and cardiac magnetic resonance data) that enhances risk stratification for patients with Takotsubo syndrome.The secondary objectives of this registry are as follows:Investigate the diagnostic value of cardiac magnetic resonance parameters in predicting in-hospital and long-term outcomes in patients with Takotsubo syndrome.Compare the proposed risk stratification score for patients with Takotsubo syndrome with previously existing scores.Investigate the contribution of machine learning models in predicting in-hospital and long-term outcomes compared to standard clinical scores.The design and rationale of this registry are available at 10.1097/RTI.0000000000000709, conditionsModule conditions: Takotsubo Cardiomyopathy, conditions: Machine Learning, conditions: Magnetic Resonance Imaging, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 350, type: ESTIMATED, outcomesModule primaryOutcomes measure: All-cause mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Cagliari, status: RECRUITING, city: Cagliari, zip: 09100, country: Italy, contacts name: Riccardo Cau, role: CONTACT, phone: +393393493317, email: riccardo.cau@unica.it, contacts name: Luca Saba, role: PRINCIPAL_INVESTIGATOR, contacts name: Riccardo Cau, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.23054, lon: 9.11917, hasResults: False
protocolSection identificationModule nctId: NCT06277284, orgStudyIdInfo id: MG-K10-I-002, briefTitle: Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-10-23, primaryCompletionDateStruct date: 2024-01-26, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Shanghai Mabgeek Biotech.Co.Ltd, class: OTHER_GOV, collaborators name: The Second Hospital of Anhui Medical University, descriptionModule briefSummary: Research Topics A randomized, open-label, parallel-group, phase I clinical trial comparing the pharmacokinetics of MG-K10 humanized monoclonal antibody in healthy adults, conditionsModule conditions: Pharmacokinetics, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: MG-K10 humanized monoclonal antibody injection (prefilled syringe), interventions name: MG-K10 humanized monoclonal antibody injection（Penicillin bottle）, outcomesModule primaryOutcomes measure: Pharmacokinetic: the maximum concentration (Cmax), primaryOutcomes measure: Pharmacokinetic: area under the curve of o~t, primaryOutcomes measure: Pharmacokinetic: area under the curve of o~∞, secondaryOutcomes measure: Safety evaluation index, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Second Affiliated Hospital of Anhui Medical University, city: Hefei, state: Anhui, zip: 230061, country: China, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06277271, orgStudyIdInfo id: 1901611-9, briefTitle: E-cigarettes as a Harm Reduction Strategy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-20, primaryCompletionDateStruct date: 2024-02-20, completionDateStruct date: 2024-03-20, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Prisma Health-Upstate, class: OTHER, collaborators name: Clemson University, descriptionModule briefSummary: E-cigarettes have emerged as an effective strategy for replacing cigarettes among smokers from the general population, but there is a dearth of studies investigating their utility in replacing cigarettes among smokers with opioid use disorder (OUD). This study aims to evaluate the feasibility and acceptability of implementing a cigarette harm reduction intervention involving e-cigarettes in office-based buprenorphine clinics., conditionsModule conditions: Smoking, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: E-cigarette, outcomesModule primaryOutcomes measure: Percentage of people who are eligible, primaryOutcomes measure: Percentage of consented participants, primaryOutcomes measure: Percentage of participants who report using the e-cigarette at least once a day, primaryOutcomes measure: Percentage of participants with at least one puff of study e-cigarette, primaryOutcomes measure: Percentage of daily diary completed, secondaryOutcomes measure: Cigarette dependence measured via the Fagerstrom test for nicotine dependence, secondaryOutcomes measure: Cigarette demand measured via the cigarette purchase task, secondaryOutcomes measure: Combustible cigarette smoking, secondaryOutcomes measure: Switching to e-cigarettes, secondaryOutcomes measure: Smoking reduction, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Prisma Health, status: RECRUITING, city: Greenville, state: South Carolina, zip: 29609, country: United States, contacts name: Alain Litwin, MD, role: CONTACT, phone: 864-455-5648, email: alain.litwin@prismahealth.org, geoPoint lat: 34.85262, lon: -82.39401, hasResults: False
protocolSection identificationModule nctId: NCT06277245, orgStudyIdInfo id: LK001303, briefTitle: A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-06, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Lynk Pharmaceuticals Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable).The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy., conditionsModule conditions: Atopic Dermatitis, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 354, type: ESTIMATED, armsInterventionsModule interventions name: LNK01001, interventions name: Placebo, outcomesModule primaryOutcomes measure: Eczema Area and Severity Index (EASI-75) at Week 16, primaryOutcomes measure: Investigator's Global Assessment (IGA) score of 0/1 at Week 16, secondaryOutcomes measure: Worst-Itch Numeric Rating Scale (WI-NRS-4)-4 at Week 16, secondaryOutcomes measure: Worst-Itch Numeric Rating Scale (WI-NRS-4)-4 at all visits other than Week 16., secondaryOutcomes measure: Change from Baseline in Eczema Area and Severity Index at all visits., secondaryOutcomes measure: Eczema Area and Severity Index (EASI 75) at all visits other than Week 16, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dermatological Hospital of Southern Medical University, status: RECRUITING, city: Guangzhou, country: China, contacts name: Bing Yang, Doctor, role: CONTACT, phone: 020-87257353, email: yangbin101@hotmail.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06277206, orgStudyIdInfo id: FAPIPDAC02, briefTitle: A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-08-04, primaryCompletionDateStruct date: 2023-11-19, completionDateStruct date: 2024-02-10, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, descriptionModule briefSummary: To explore the potential utility of 18F-FAPI-04 PET/CT for pathologic response evaluation to systemic treatment in PDAC, conditionsModule conditions: 18F-FAPI, conditions: Pancreas Adenocarcinoma, conditions: Systemic Treatment, conditions: Pathologic Response, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 59, type: ACTUAL, armsInterventionsModule interventions name: 18F-FAPI PET/CT, outcomesModule primaryOutcomes measure: Change of Maximum standardized uptake value, primaryOutcomes measure: Change of Mean standardized uptake value, secondaryOutcomes measure: Maximum standardized uptake value, secondaryOutcomes measure: Mean standardized uptake value, secondaryOutcomes measure: Metabolic Tumor Volume, secondaryOutcomes measure: Total Lesion FAP expression, secondaryOutcomes measure: Change of Metabolic Tumor Volume, secondaryOutcomes measure: Change of Total Lesion FAP expression, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: First Affiliated Hospital, Medical College of Zhejiang University, city: Hangzhou, state: Zhejiang, zip: 310003, country: China, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06277180, orgStudyIdInfo id: TCR-FAPI for MTC Surgery, briefTitle: 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, class: OTHER, collaborators name: Peking University, collaborators name: Peking University Cancer Hospital & Institute, descriptionModule briefSummary: This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level., conditionsModule conditions: Medullary Thyroid Cancer, conditions: Prositron Emission Tomography, conditions: Fibroblast Activation Protein Inhibitor, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Surgery, interventions name: Surgery, outcomesModule primaryOutcomes measure: 1-month post-surgery calcitonin level, secondaryOutcomes measure: 2-year event free survival, secondaryOutcomes measure: Ratio of patient that change surgical plan, secondaryOutcomes measure: Accuracy, sensitivity, specificity of 68Ga-TCR-FAPI PET/CT in identifying MTC lesions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, status: RECRUITING, city: Beijing, zip: 100021, country: China, contacts name: Shaoyan Liu, M.D., role: CONTACT, phone: 0086-010-87787190, email: shaoyanliu.bj@263.net, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06277154, orgStudyIdInfo id: MASCT-I-2004, briefTitle: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2026-02, completionDateStruct date: 2027-02, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: HRYZ Biotech Co., class: INDUSTRY, descriptionModule briefSummary: This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma., conditionsModule conditions: Leiomyosarcoma, conditions: Liposarcoma, conditions: Synovial Sarcoma, conditions: Angiosarcoma, conditions: Undifferentiated Pleomorphic Sarcoma, conditions: Epithelioid Sarcoma, conditions: Malignant Peripheral Nerve Sheath Tumors, conditions: Fibrosarcoma, conditions: Pleomorphic Rhabdomyosarcoma, conditions: Endometrial Stromal Sarcoma, conditions: Desmoplastic Small Round Cell Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 148, type: ESTIMATED, armsInterventionsModule interventions name: MASCT-I, interventions name: Doxorubicin, interventions name: Ifosfamide, outcomesModule primaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of response (DoR), secondaryOutcomes measure: Adverse events and serious adverse events, secondaryOutcomes measure: Adverse events and serious adverse events related to MASCT-I, secondaryOutcomes measure: Rate and severity of clinically-significant abnormalities in laboratory testings, otherOutcomes measure: Immune response to tumor-associated antigens, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, city: Guangzhou, country: China, contacts name: Xing Zhang, role: CONTACT, email: zhangxing@sysucc.org.cn, contacts name: Xing Zhang, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06277141, orgStudyIdInfo id: M230742, briefTitle: The Vitality Mammography Messaging Study, acronym: VMS, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-09-27, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Wits Health Consortium (Pty) Ltd, class: OTHER, collaborators name: Discovery Vitality, descriptionModule briefSummary: The investigators will be conducting a randomized controlled trial amongst members of a Wellness Program to test receipt of mammogram using the Whatsapp social media platform and testing various messages., conditionsModule conditions: Breast Cancer Female, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled trial, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 6665, type: ESTIMATED, armsInterventionsModule interventions name: Standard message, interventions name: Radiology booking site link., interventions name: Radiology practice telephone numbers, interventions name: Radiology site link and telephone numbers, outcomesModule primaryOutcomes measure: Comparison of mammography screening rates using WhatsApp, eligibilityModule sex: FEMALE, minimumAge: 50 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Witwatersrand, city: Johannesburg, state: Gauteng, country: South Africa, geoPoint lat: -26.20227, lon: 28.04363, hasResults: False